Commercial
Advanced Search
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
8dcdf2a5-f8fc-4142-8899-7625f99f1839.aspx
  
08.00.62oAbatacept(Orencia®)forInjectionforIntravenousUse08.00.62oPharmacy (08)Abatacept (Orencia®) for Injection for Intravenous Use8dcdf2a5-f8fc-4142-8899-7625f99f18395665Abatacept (Orencia®) for Injection for Intravenous Use08.00.62
{"5666": {"Id":5666,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":7706,"PolicyAttachmentPageName":"509091c9-2d21-4698-bcb8-ba5842391c9a"},}
e4ec1d8c-da31-4dc8-b923-961a39eb81ca.aspx
  
12.00.01hAcupuncture12.00.01hMiscellaneous (12)Acupuncturee4ec1d8c-da31-4dc8-b923-961a39eb81ca5582Acupuncture12.00.01
{"5583": {"Id":5583,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Acupuncture","MPPolicyAttachmentInternalSourceId":7650,"PolicyAttachmentPageName":"47adaae8-a5cc-41fb-adcd-f1d8ac5e952b"},}
0c4536db-f2b2-4ce8-8029-a0a1d6b3d92b.aspx
  
12.04.04bAcuteCareFacilityInpatientTransfers12.04.04bMiscellaneous (12)Acute Care Facility Inpatient Transfers0c4536db-f2b2-4ce8-8029-a0a1d6b3d92b5453Acute Care Facility Inpatient Transfers12.04.04
839b21f4-dacb-4c09-ab51-ee66bbe07f5f.aspx
  
08.01.11hAdo-TrastuzumabEmtansine(Kadcyla®)08.01.11hPharmacy (08)Ado-Trastuzumab Emtansine (Kadcyla®)839b21f4-dacb-4c09-ab51-ee66bbe07f5f4879Ado-Trastuzumab Emtansine (Kadcyla®)08.01.11
{"4880": {"Id":4880,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes and Narratives","MPPolicyAttachmentInternalSourceId":6792,"PolicyAttachmentPageName":"5ec33a2f-b084-411c-a40a-e217523ca6a2"},}
62f7ab0b-f175-47c9-a8c3-1b9de01b6521.aspx
  
08.00.69cAgalsidasebeta(Fabrazyme®)08.00.69cPharmacy (08)Agalsidase beta (Fabrazyme®)62f7ab0b-f175-47c9-a8c3-1b9de01b65215088Agalsidase beta (Fabrazyme®)08.00.69
3db4601a-995f-4459-b142-6f30f15b670a.aspx
  
12.04.03cAirAmbulanceServices12.04.03cMiscellaneous (12)Air Ambulance Services3db4601a-995f-4459-b142-6f30f15b670a5358Air Ambulance Services12.04.03
5cc13039-207a-45c4-91f6-c7c4d3e6778a.aspx
  
08.01.22dAlemtuzumab(Lemtrada®)08.01.22dPharmacy (08)Alemtuzumab (Lemtrada®)5cc13039-207a-45c4-91f6-c7c4d3e6778a5227Alemtuzumab (Lemtrada®)08.01.22
55b349d1-264d-43aa-9a17-4ece583a6923.aspx
  
08.00.72kAlglucosidasealfa(e.g.,Lumizyme®),Avalglucosidasealfa-ngpt(Nexviazyme®)08.00.72kPharmacy (08)Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® )55b349d1-264d-43aa-9a17-4ece583a69235281Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® )08.00.72
aa555f38-c3ef-429e-990c-f633f79e8ada.aspx
  
07.00.21jAllergyImmunotherapy07.00.21jMedicine (07)Allergy Immunotherapyaa555f38-c3ef-429e-990c-f633f79e8ada4754Allergy Immunotherapy07.00.21
cd295dbf-3ea0-44ef-93bf-207a1a2b64e8.aspx
  
08.01.88AllogeneicProcessedThymusTissue-agdc(Rethymic®)08.01.88Pharmacy (08)Allogeneic Processed Thymus Tissue-agdc (Rethymic®)cd295dbf-3ea0-44ef-93bf-207a1a2b64e85103Allogeneic Processed Thymus Tissue-agdc (Rethymic®)08.01.88
418d9a77-331d-4b0e-81fd-b74f8fdcec75.aspx
  
06.02.29dAlloMap™MolecularExpressionTestingforHeartTransplantRejection(IndependenceAdministrators)06.02.29dPathology and Laboratory (06)AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)418d9a77-331d-4b0e-81fd-b74f8fdcec755148AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)06.02.29
1b5f038c-0f20-4a75-98b9-9166968f5086.aspx
  
08.00.91eAlpha1-AntitrypsinTherapy(e.g.,Prolastin-C®,AralastNP®,Glassia®,Zemaira®)08.00.91ePharmacy (08)Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)1b5f038c-0f20-4a75-98b9-9166968f50865154Alpha 1-Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)08.00.91
96e18171-9a5d-4545-887f-e5cfa53e1e1a.aspx
  
00.01.52sAlwaysBundledProcedureCodes00.01.52sAdministrative (00)Always Bundled Procedure Codes96e18171-9a5d-4545-887f-e5cfa53e1e1a5441Always Bundled Procedure Codes00.01.52
{"5442": {"Id":5442,"MPAttachmentLetter":"B","Title":"Procedures/Services Not Eligible for Separate Reimbursement","MPPolicyAttachmentInternalSourceId":7487,"PolicyAttachmentPageName":"da557f26-d6f5-4533-a932-93cd18364b2b"},"5443": {"Id":5443,"MPAttachmentLetter":"A","Title":"Always Bundled Procedures (Indicator B)","MPPolicyAttachmentInternalSourceId":7488,"PolicyAttachmentPageName":"c86880e2-0e58-4182-bff2-bb1c0520c730"},"5444": {"Id":5444,"MPAttachmentLetter":"C","Title":"Procedures/Services Not Eligible for Reimbursement","MPPolicyAttachmentInternalSourceId":7489,"PolicyAttachmentPageName":"333e9fdb-a64c-4337-8b55-dd60b0512f74"},}
8be8c224-7982-4c73-97fa-a4da013f34a5.aspx
  
07.02.09iAmbulatoryBloodPressureMonitoring(ABPM)andHomeBloodPressureMonitoring(HBPM)Devices07.02.09iMedicine (07)Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices8be8c224-7982-4c73-97fa-a4da013f34a55587Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices07.02.09
ba856f28-0a01-4798-a70e-b7b77c8ec552.aspx
  
07.02.21mAmbulatoryElectrocardiography(AECG)MonitoringandMobileCardiacOutpatientTelemetry(MCOT)Monitoring07.02.21mMedicine (07)Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoringba856f28-0a01-4798-a70e-b7b77c8ec5525595Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring07.02.21
d106c24d-bf01-4f50-8f0f-3e0547ca3f89.aspx
  
01.00.12bAnesthesiaServicesforEpidural,ParavertebralFacetandSacroiliacJointInjectionsforSpinalJointManagement01.00.12bAnesthesia (01)Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Managementd106c24d-bf01-4f50-8f0f-3e0547ca3f895591Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management01.00.12
{"5592": {"Id":5592,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7647,"PolicyAttachmentPageName":"3f46dfc2-2dbb-4e64-aee9-86ce5fe7f424"},}
1f28d243-9551-4828-b937-721f7e6de07a.aspx
  
08.01.82bAnifrolumab-fnia(Saphnelo®)08.01.82bPharmacy (08)Anifrolumab-fnia (Saphnelo®)1f28d243-9551-4828-b937-721f7e6de07a5349Anifrolumab-fnia (Saphnelo®)08.01.82
35274498-d997-4f99-94a3-0d42f685e2be.aspx
  
05.00.39sAnkle-Foot/Knee-Ankle-FootOrthoses05.00.39sDME (05)Ankle-Foot/Knee-Ankle-Foot Orthoses35274498-d997-4f99-94a3-0d42f685e2be5084Ankle-Foot/Knee-Ankle-Foot Orthoses05.00.39
{"5085": {"Id":5085,"MPAttachmentLetter":"A","Title":"HCPCS Codes","MPPolicyAttachmentInternalSourceId":7044,"PolicyAttachmentPageName":"b121dd27-32ef-4c9d-a81a-a61ed2b9126f"},}
36aee0bb-d271-4e94-8256-eafdfce45397.aspx
  
06.03.04nApheresisTherapy06.03.04nPathology and Laboratory (06)Apheresis Therapy36aee0bb-d271-4e94-8256-eafdfce453972774Apheresis Therapy06.03.04
76f815fa-14c4-4531-8c3f-bc8fe0de4f6f.aspx
  
11.08.05gApplicationandRemovalofTattoos11.08.05gSurgery (11)Application and Removal of Tattoos76f815fa-14c4-4531-8c3f-bc8fe0de4f6f5032Application and Removal of Tattoos11.08.05
8e21f681-8261-4b8d-924b-59e9f4a8b449.aspx
  
14.00.03AppliedBehaviorAnalysis(ABA)fortheTreatmentofAutismSpectrumDisorders(ASD)14.00.03Behavioral Health (14)Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorders (ASD)8e21f681-8261-4b8d-924b-59e9f4a8b4494967Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorders (ASD)14.00.03
68b0db08-bc36-4791-bc21-24234f4c1097.aspx
  
08.01.41eAprepitant(Cinvanti™),FosaprepitantDimeglumine(Emend®),Granisetron(Sustol®),andRolapitant(Varubi®)08.01.41ePharmacy (08)Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)68b0db08-bc36-4791-bc21-24234f4c10974923Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)08.01.41
{"4924": {"Id":4924,"MPAttachmentLetter":"A","Title":"Risk of Emesis Without Prophylaxis: Intravenous and Oral Antineoplastic Agents","MPPolicyAttachmentInternalSourceId":7122,"PolicyAttachmentPageName":"fe7db1ca-7fea-41ca-8b4d-26bae30635bf"},}
247cb6c3-4717-4406-9763-45a7e18e9743.aspx
  
11.05.16lAqueousShunts,Microstents,Viscocanalostomy,andCanaloplastyfortheTreatmentofGlaucoma11.05.16lSurgery (11)Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma247cb6c3-4717-4406-9763-45a7e18e97434928Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma11.05.16
{"4929": {"Id":4929,"MPAttachmentLetter":"A","Title":"ICD-10 codes","MPPolicyAttachmentInternalSourceId":7061,"PolicyAttachmentPageName":"a0d68167-5052-4bab-8ea3-c25cff7e560b"},}
ec54656d-1d31-41b0-b458-e1a4358b0ed7.aspx
  
11.14.19pArtificialIntervertebralCervicalDiscInsertion(IndependenceAdministrators)11.14.19pSurgery (11)Artificial Intervertebral Cervical Disc Insertion (Independence Administrators)ec54656d-1d31-41b0-b458-e1a4358b0ed75233Artificial Intervertebral Cervical Disc Insertion (Independence Administrators)11.14.19
1a1546d8-2f70-47e9-80e8-be03e5acd487.aspx
  
11.15.31bArtificialIntervertebralLumbarDiscInsertion11.15.31bSurgery (11)Artificial Intervertebral Lumbar Disc Insertion1a1546d8-2f70-47e9-80e8-be03e5acd4874919Artificial Intervertebral Lumbar Disc Insertion11.15.31
5caa8913-7c03-4a9a-a9df-9b90a880523a.aspx
  
08.01.35gAsparaginaseErwiniaChrysanthemi(Erwinaze®),asparaginaseerwiniachrysanthemi(recombinant)-rywn(Rylaze®)08.01.35gPharmacy (08)Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze®)5caa8913-7c03-4a9a-a9df-9b90a880523a5371Asparaginase Erwinia Chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze®)08.01.35
07b6094a-2341-4bed-a1b8-841e3fe33dcc.aspx
  
06.02.27nAssaysofGeneticExpressioninTumorTissueforBreastCancerPrognosis(IndependenceAdministrators)06.02.27nPathology and Laboratory (06)Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)07b6094a-2341-4bed-a1b8-841e3fe33dcc5474Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)06.02.27
76727854-57be-4f5a-a359-c836ddd2fe12.aspx
  
07.10.06iAssistedReproductiveTechnologyforInfertilityandOocyteCryopreservation07.10.06iMedicine (07)Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation76727854-57be-4f5a-a359-c836ddd2fe124795Assisted Reproductive Technology for Infertility and Oocyte Cryopreservation07.10.06
ab4a9746-3c0a-4512-bd38-0b178d74977d.aspx
  
08.01.69cAtezolizumab(Tecentriq®)08.01.69cPharmacy (08)Atezolizumab (Tecentriq®)ab4a9746-3c0a-4512-bd38-0b178d74977d5045Atezolizumab (Tecentriq®)08.01.69
{"5046": {"Id":5046,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7179,"PolicyAttachmentPageName":"0d497a54-8cfd-430b-9dff-dd040a596b3c"},}
561dc9ad-1c1e-407e-9e75-bd02a965bf10.aspx
  
11.14.06jAutologousChondrocyteImplantation(ACI)andOtherCell-basedTreatmentsofFocalArticularCartilageLesions(IndependenceAdministrators)11.14.06jSurgery (11)Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)561dc9ad-1c1e-407e-9e75-bd02a965bf105162Autologous Chondrocyte Implantation (ACI) and Other Cell-based Treatments of Focal Articular Cartilage Lesions (Independence Administrators)11.14.06
de68459f-cd9d-4108-a14e-398f4455f8a8.aspx
  
05.00.29oAutomaticExternalCardioverterDefibrillators(WearableandNonwearable)05.00.29oDME (05)Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)de68459f-cd9d-4108-a14e-398f4455f8a85596Automatic External Cardioverter Defibrillators (Wearable and Nonwearable)05.00.29
{"5597": {"Id":5597,"MPAttachmentLetter":"B","Title":"ICD-10 codes used to represent the Nonwearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":7702,"PolicyAttachmentPageName":"2ac8befd-4776-4224-8cdc-8ea56fd0ab32"},"5598": {"Id":5598,"MPAttachmentLetter":"A","Title":"ICD-10 Codes used to represent the Wearable Automatic External Defibrillator (AED):","MPPolicyAttachmentInternalSourceId":7703,"PolicyAttachmentPageName":"a848bbd6-6bba-49f9-85aa-b02e7fe5f1f2"},}
6acca538-d91c-41c4-a64c-7e8d2930e58c.aspx
  
07.03.23fAutonomicNervousSystemTesting07.03.23fMedicine (07)Autonomic Nervous System Testing6acca538-d91c-41c4-a64c-7e8d2930e58c5262Autonomic Nervous System Testing07.03.23
89f5a884-1725-46ed-91bb-b7944b71287c.aspx
  
08.01.64bAvelumab(Bavencio®)08.01.64bPharmacy (08)Avelumab (Bavencio®)89f5a884-1725-46ed-91bb-b7944b71287c4888Avelumab (Bavencio®)08.01.64
{"4889": {"Id":4889,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7008,"PolicyAttachmentPageName":"dd583577-e9f1-40f6-8c23-ea98e3eaedbc"},}
24f38e25-4fbe-4329-b23f-2b507113624c.aspx
  
11.16.06jBalloonCatheterDilationofSinusOstiaforTreatmentofChronicRhinosinusitis11.16.06jSurgery (11)Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis24f38e25-4fbe-4329-b23f-2b507113624c5021Balloon Catheter Dilation of Sinus Ostia for Treatment of Chronic Rhinosinusitis11.16.06
e2e22104-ada2-4d84-9c71-c600f1ea170e.aspx
  
11.03.02tBariatricSurgery11.03.02tSurgery (11)Bariatric Surgerye2e22104-ada2-4d84-9c71-c600f1ea170e2791Bariatric Surgery11.03.02
{"2792": {"Id":2792,"MPAttachmentLetter":"A","Title":"Body Mass Index (BMI) Charts","MPPolicyAttachmentInternalSourceId":4907,"PolicyAttachmentPageName":"292a20ba-ec48-442c-a624-40100880cb31"},"2793": {"Id":2793,"MPAttachmentLetter":"B","Title":"Tanner Staging System Criteria for Adolescents","MPPolicyAttachmentInternalSourceId":4908,"PolicyAttachmentPageName":"1b6da816-a2b6-4583-807a-5430c89f8392"},"2794": {"Id":2794,"MPAttachmentLetter":"C","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":4909,"PolicyAttachmentPageName":"b9184a36-7491-498e-aac9-ed1933abf92b"},}
b9da618c-f1df-4a91-bdec-7d467008d14f.aspx
  
08.00.99eBelimumab(Benlysta®)forIntravenousUse08.00.99ePharmacy (08)Belimumab (Benlysta®) for Intravenous Useb9da618c-f1df-4a91-bdec-7d467008d14f5225Belimumab (Benlysta®) for Intravenous Use08.00.99
5835bdef-e015-458a-83ed-3ad35061c1b5.aspx
  
08.02.10BeremageneGeperpavec(Vyjuvek™)08.02.10Pharmacy (08)Beremagene Geperpavec (Vyjuvek™)5835bdef-e015-458a-83ed-3ad35061c1b55528Beremagene Geperpavec (Vyjuvek™)08.02.10
a621d3f8-8991-44aa-9f0c-83bd74ddb3aa.aspx
  
08.01.89BetibeglogeneAutotemcel[Beti-Cel(ZYNTEGLO®)]08.01.89Pharmacy (08)Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)]a621d3f8-8991-44aa-9f0c-83bd74ddb3aa4900Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)]08.01.89
4f5fba6f-e0af-4ca7-ae67-ee9a82fff8e6.aspx
  
08.00.66uBevacizumab(Avastin®)andRelatedBiosimilarsForOncologicUse08.00.66uPharmacy (08)Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use4f5fba6f-e0af-4ca7-ae67-ee9a82fff8e65313Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use08.00.66
{"5314": {"Id":5314,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":7256,"PolicyAttachmentPageName":"b25c28fb-b5eb-4152-9bca-95087ce19862"},"5315": {"Id":5315,"MPAttachmentLetter":"B","Title":"ICD 10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":7322,"PolicyAttachmentPageName":"bdf82e0b-98c1-4c3c-8545-71d281a15389"},}
947f2068-3357-4b3b-a661-61dc273ccbf7.aspx
  
00.10.39pBillingforProfessionalOffice-BasedServicesPerformedinanOutpatientOffice-BasedSettingLocatedwithinaFacilityoronaFacilityCampus00.10.39pAdministrative (00)Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus947f2068-3357-4b3b-a661-61dc273ccbf75006Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus00.10.39
{"5007": {"Id":5007,"MPAttachmentLetter":"A","Title":"Billing for Professional Office-Based Services Performed in an Outpatient Office-Based Setting Located within a Facility or on a Facility Campus","MPPolicyAttachmentInternalSourceId":7191,"PolicyAttachmentPageName":"7fa7063b-493d-48fa-8a2b-dca1075b3ba1"},}
7467b7be-328a-4664-89ab-13b4c0859839.aspx
  
00.10.38aBillingRequirementsforMultipleBirthsforProfessionalProviders00.10.38aAdministrative (00)Billing Requirements for Multiple Births for Professional Providers7467b7be-328a-4664-89ab-13b4c08598393051Billing Requirements for Multiple Births for Professional Providers00.10.38
{"3052": {"Id":3052,"MPAttachmentLetter":"A","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ROUTINE OBSTETRIC (GLOBALE MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5340,"PolicyAttachmentPageName":"d157b661-7eea-46ea-ab0f-b6ec2bd15a87"},"3053": {"Id":3053,"MPAttachmentLetter":"B","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF TWINS WHEN ANETEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5341,"PolicyAttachmentPageName":"5d22c25e-12c7-42e4-a127-e50b59895309"},"3054": {"Id":3054,"MPAttachmentLetter":"C","Title":"CODING SCENARIOS FOR REPORTING HIGH-ORDER MULTIPLE (TRIPLETS, QUADRUPLETS, ETC) BIRTHS WHEN ROUTINE OBSTETRIC (GLOBAL MATERNITY/OBSTETRIC [OB]) CARE WAS PROVIDED","MPPolicyAttachmentInternalSourceId":5342,"PolicyAttachmentPageName":"d0a0d176-67d6-4d41-9e52-2cbec1ebff3d"},"3055": {"Id":3055,"MPAttachmentLetter":"D","Title":"MULTIPLE BIRTH CODING SCENARIOS FOR DELIVERY OF HIGH-ORDER MULTIPLES WHEN ANTEPARTUM CARE IS NOT PROVIDED","MPPolicyAttachmentInternalSourceId":5343,"PolicyAttachmentPageName":"74d58125-3d75-4d7b-8d89-cbaebd03cc03"},}
b9eca923-cb25-460f-a4e1-f8c7f677f0dc.aspx
  
07.00.01kBiofeedbackTherapy07.00.01kMedicine (07)Biofeedback Therapyb9eca923-cb25-460f-a4e1-f8c7f677f0dc5584Biofeedback Therapy07.00.01
29688998-d529-4d00-a44e-0c35fc955865.aspx
  
07.06.03bBioimpedencefortheDetectionofLymphedema07.06.03bMedicine (07)Bioimpedence for the Detection of Lymphedema29688998-d529-4d00-a44e-0c35fc9558655549Bioimpedence for the Detection of Lymphedema07.06.03
0004caa3-4725-461b-a8f6-5dc4564e1a27.aspx
  
11.05.02jBlepharoplasty,RepairofBlepharoptosis,RepairofBrowPtosis,andCanthoplasty/Canthopexy11.05.02jSurgery (11)Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy0004caa3-4725-461b-a8f6-5dc4564e1a274779Blepharoplasty, Repair of Blepharoptosis, Repair of Brow Ptosis, and Canthoplasty/Canthopexy11.05.02
{"4780": {"Id":4780,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":6997,"PolicyAttachmentPageName":"192874a4-9925-4785-8097-96d4fd434cf0"},}
210e5872-ee1f-4197-bbec-c07c8d759d25.aspx
  
08.01.21fBlinatumomab(Blincyto®)08.01.21fPharmacy (08)Blinatumomab (Blincyto®)210e5872-ee1f-4197-bbec-c07c8d759d255039Blinatumomab (Blincyto®)08.01.21
1fb1fc21-ec60-4063-8a80-24e2d8b0722b.aspx
  
11.01.06gBone-Anchored(Osseointegrated)HearingAidsandImplantableMiddleEarHearingAids11.01.06gSurgery (11)Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids1fb1fc21-ec60-4063-8a80-24e2d8b0722b5517Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids11.01.06
bff42d60-1485-44e5-b4a3-205018d75d2c.aspx
  
09.00.04nBoneMineralDensity(BMD)Testing09.00.04nRadiology (09)Bone Mineral Density (BMD) Testingbff42d60-1485-44e5-b4a3-205018d75d2c5438Bone Mineral Density (BMD) Testing09.00.04
8e1a98cc-e6ac-495f-b620-443f9ce81970.aspx
  
08.00.73pBortezomib(BortezomibforInjection,Velcade®)08.00.73pPharmacy (08)Bortezomib (Bortezomib for Injection, Velcade®)8e1a98cc-e6ac-495f-b620-443f9ce819705655Bortezomib (Bortezomib for Injection, Velcade®)08.00.73
{"5656": {"Id":5656,"MPAttachmentLetter":"A","Title":"ICD-10 Codes and Narratives","MPPolicyAttachmentInternalSourceId":7708,"PolicyAttachmentPageName":"15a997f7-8e96-4155-8288-a0a7b83b0fbc"},}
63ff1f25-460c-41d0-ac3f-8a39a904535e.aspx
  
08.00.26abBotulinumToxinAgents08.00.26abPharmacy (08)Botulinum Toxin Agents63ff1f25-460c-41d0-ac3f-8a39a904535e5661Botulinum Toxin Agents08.00.26
{"5662": {"Id":5662,"MPAttachmentLetter":"A","Title":"ICD-10 Diagnosis Codes","MPPolicyAttachmentInternalSourceId":7744,"PolicyAttachmentPageName":"62116ca7-2b9a-4915-b1a1-cd53e36a9bdc"},}
590723a8-759b-4b63-953f-9224ae10d439.aspx
  
09.00.10zBrachytherapyandAcceleratedWholeBreastIrradiationusingThree-DimensionalConformationRadiationTherapy09.00.10zRadiology (09)Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy590723a8-759b-4b63-953f-9224ae10d4394431Brachytherapy and Accelerated Whole Breast Irradiation using Three-Dimensional Conformation Radiation Therapy09.00.10
2c66e6e3-355b-468f-8023-0018ae375f9b.aspx
  
05.00.76gBreastPumps05.00.76gDME (05)Breast Pumps2c66e6e3-355b-468f-8023-0018ae375f9b4961Breast Pumps05.00.76
4ee019bd-e663-4061-9d7f-6547117431f4.aspx
  
08.01.13hBrentuximabVedotin(Adcetris®)08.01.13hPharmacy (08)Brentuximab Vedotin (Adcetris®)4ee019bd-e663-4061-9d7f-6547117431f44542Brentuximab Vedotin (Adcetris®)08.01.13
{"4543": {"Id":4543,"MPAttachmentLetter":"A","Title":"ICD CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":6762,"PolicyAttachmentPageName":"722c0adb-e5cf-4d42-a2ac-eba09c2b0574"},}
7cb3c3bf-6ff2-4e8c-b0b1-0444959b368d.aspx
  
11.16.09BronchialValves11.16.09Surgery (11)Bronchial Valves7cb3c3bf-6ff2-4e8c-b0b1-0444959b368d5454Bronchial Valves11.16.09
25d7087c-ccb2-4eb7-8a83-dae2287e4fa3.aspx
  
08.01.49bBurosumab-twza(Crysvita®)08.01.49bPharmacy (08)Burosumab-twza (Crysvita®)25d7087c-ccb2-4eb7-8a83-dae2287e4fa35282Burosumab-twza (Crysvita®)08.01.49
51cf7e36-9d4b-4e2b-a76c-03082412b979.aspx
  
08.01.51bCanakinumab(Ilaris®)08.01.51bPharmacy (08)Canakinumab (Ilaris®)51cf7e36-9d4b-4e2b-a76c-03082412b9795289Canakinumab (Ilaris®)08.01.51
bdafb220-b1ee-4cdb-b16a-255523765a60.aspx
  
10.01.01pCardiacRehabilitation(CR)andIntensiveCardiacRehabilitation(ICR)Programs10.01.01pRehabilitation Services (10)Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programsbdafb220-b1ee-4cdb-b16a-255523765a605605Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs10.01.01
{"5606": {"Id":5606,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7736,"PolicyAttachmentPageName":"270d00a9-e342-4fd3-b29c-d140a0c5636c"},}
142a9bb0-7fee-4470-89dd-7f8c7299962c.aspx
  
00.01.59mCareManagementandCarePlanningServices00.01.59mAdministrative (00)Care Management and Care Planning Services142a9bb0-7fee-4470-89dd-7f8c7299962c5008Care Management and Care Planning Services00.01.59
ea938bae-5423-4dc6-be25-b35f3444277f.aspx
  
08.01.05iCarfilzomib(Kyprolis®)08.01.05iPharmacy (08)Carfilzomib (Kyprolis®)ea938bae-5423-4dc6-be25-b35f3444277f4747Carfilzomib (Kyprolis®)08.01.05
76b13cf3-92b8-4525-b937-062890962486.aspx
  
00.10.15dCastandSplintApplicationsandAssociatedSupplies00.10.15dAdministrative (00)Cast and Splint Applications and Associated Supplies76b13cf3-92b8-4525-b937-0628909624864299Cast and Splint Applications and Associated Supplies00.10.15
{"4300": {"Id":4300,"MPAttachmentLetter":"A","Title":"Procedure Codes Related to Cast and Splint Applications and Associated Supplies","MPPolicyAttachmentInternalSourceId":6421,"PolicyAttachmentPageName":"ef40cfc7-9301-40ac-955b-042c21374443"},}
f794b752-3310-4f3a-a3ae-80e0ae54c3fe.aspx
  
11.01.07fCataractSurgery11.01.07fSurgery (11)Cataract Surgeryf794b752-3310-4f3a-a3ae-80e0ae54c3fe4788Cataract Surgery11.01.07
{"4789": {"Id":4789,"MPAttachmentLetter":"A","Title":"ICD 10 codes for policy 11.01.07d, Cataract Surgery","MPPolicyAttachmentInternalSourceId":6668,"PolicyAttachmentPageName":"a519d3f3-aa39-4f1b-a2e9-6abe8e559016"},}
cf69ee77-98e8-491d-9266-6d8e4b6e5f94.aspx
  
11.02.06qCatheterAblationofCardiacArrhythmias11.02.06qSurgery (11)Catheter Ablation of Cardiac Arrhythmiascf69ee77-98e8-491d-9266-6d8e4b6e5f945602Catheter Ablation of Cardiac Arrhythmias11.02.06
3f34cb7e-a0e5-43f0-9d38-caed6786f817.aspx
  
08.01.66cCemiplimab-rwlc(Libtayo®)08.01.66cPharmacy (08)Cemiplimab-rwlc (Libtayo®)3f34cb7e-a0e5-43f0-9d38-caed6786f8175482Cemiplimab-rwlc (Libtayo®)08.01.66
a8bbd22a-8279-42e6-bce7-e23c36601e5f.aspx
  
08.01.39cCerliponasealfa(Brineura®)08.01.39cPharmacy (08)Cerliponase alfa (Brineura®)a8bbd22a-8279-42e6-bce7-e23c36601e5f5266Cerliponase alfa (Brineura®)08.01.39
7db4611a-daa5-4bb7-9dd6-fbec48738550.aspx
  
05.00.61gCervicalTractionDevicesforIn-homeUse05.00.61gDME (05)Cervical Traction Devices for In-home Use7db4611a-daa5-4bb7-9dd6-fbec487385505108Cervical Traction Devices for In-home Use05.00.61
1d2fc37e-88d7-431a-9aca-e9f20e57b894.aspx
  
08.00.67nCetuximab(Erbitux®)08.00.67nPharmacy (08)Cetuximab (Erbitux®)1d2fc37e-88d7-431a-9aca-e9f20e57b8944944Cetuximab (Erbitux®)08.00.67
{"4945": {"Id":4945,"MPAttachmentLetter":"B","Title":"ICD-10 Codes for Cetuximab (Erbitux®)","MPPolicyAttachmentInternalSourceId":7025,"PolicyAttachmentPageName":"3076dda0-2a35-4c44-8472-ddea1e48e6a6"},"4946": {"Id":4946,"MPAttachmentLetter":"A","Title":"Dosing and Frequency Requirements","MPPolicyAttachmentInternalSourceId":7026,"PolicyAttachmentPageName":"f158ffaa-9a1b-498f-af64-a68cee2d7dfa"},}
7d28d8ee-4fcf-48ac-aaee-cfd8b31c3bfb.aspx
  
11.08.08hChemicalPeels11.08.08hSurgery (11)Chemical Peels7d28d8ee-4fcf-48ac-aaee-cfd8b31c3bfb4537Chemical Peels11.08.08
74afbcd9-65f3-4d96-bd95-8995043065c0.aspx
  
08.01.43kChimericAntigenReceptor(CAR)Therapy08.01.43kPharmacy (08)Chimeric Antigen Receptor (CAR) Therapy74afbcd9-65f3-4d96-bd95-8995043065c04540Chimeric Antigen Receptor (CAR) Therapy08.01.43
{"4541": {"Id":4541,"MPAttachmentLetter":"A","Title":"ICD-10 CODES AND NARRATIVES","MPPolicyAttachmentInternalSourceId":6560,"PolicyAttachmentPageName":"940358e1-043e-4889-b782-fe9a11c0ad48"},}
f970c42c-dd59-466f-8b6a-9f941ed5693c.aspx
  
10.02.02jChiropracticSpinalandExtraspinalManipulationTherapy10.02.02jRehabilitation Services (10)Chiropractic Spinal and Extraspinal Manipulation Therapyf970c42c-dd59-466f-8b6a-9f941ed5693c4753Chiropractic Spinal and Extraspinal Manipulation Therapy10.02.02
69f9d578-6311-43f4-b6c0-afc370118818.aspx
  
08.00.92afCoagulationFactors08.00.92afPharmacy (08)Coagulation Factors69f9d578-6311-43f4-b6c0-afc3701188185412Coagulation Factors08.00.92
c5499930-95f2-444b-a13e-1ac4defdf91b.aspx
  
06.02.54cCobalamin(VitaminB12),FolicAcid,andHomocysteineTesting06.02.54cPathology and Laboratory (06)Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testingc5499930-95f2-444b-a13e-1ac4defdf91b4993Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing06.02.54
{"4994": {"Id":4994,"MPAttachmentLetter":"A","Title":"MEDICALLY NECESSARY ICD 10 CODES FOR COBALAMIN (VITAMIN B12) AND/OR FOLIC ACID TESTING (CPT CODES 82607, 82608, 82746, AND 82747)","MPPolicyAttachmentInternalSourceId":7156,"PolicyAttachmentPageName":"d03d4c64-525a-45ec-95d6-913e55453365"},}
635e99c0-9163-4b87-861e-42825b57bab9.aspx
  
11.01.02qCochlearImplantation11.01.02qSurgery (11)Cochlear Implantation635e99c0-9163-4b87-861e-42825b57bab95452Cochlear Implantation11.01.02
0371d979-7a62-4d2e-89a7-3202eff71aa6.aspx
  
08.01.71Collagenaseclostridiumhistolyticum(Xiaflex®),collagenaseclostridiumhistolyticum-aaes(Qwo™)08.01.71Pharmacy (08)Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™)0371d979-7a62-4d2e-89a7-3202eff71aa65069Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo™)08.01.71
5679ec89-5fbf-40f0-923c-6684f1f0cde1.aspx
  
11.03.12tColorectalCancerScreening11.03.12tSurgery (11)Colorectal Cancer Screening5679ec89-5fbf-40f0-923c-6684f1f0cde15368Colorectal Cancer Screening11.03.12
979c27fb-de3f-4cf5-82ba-0053b59f78b8.aspx
  
12.00.03gComplementaryandIntegrativeHealthServices12.00.03gMiscellaneous (12)Complementary and Integrative Health Services979c27fb-de3f-4cf5-82ba-0053b59f78b84301Complementary and Integrative Health Services12.00.03
df4be546-1954-4879-82ef-5b809efac655.aspx
  
07.06.01bCompleteDecongestiveTherapy(CDT)07.06.01bMedicine (07)Complete Decongestive Therapy (CDT)df4be546-1954-4879-82ef-5b809efac6555402Complete Decongestive Therapy (CDT)07.06.01
2641be91-6b2d-457f-9cb2-2fd6c8fd3704.aspx
  
11.14.30CompositeTissueAllotransplantationoftheHand(s)andFace11.14.30Surgery (11)Composite Tissue Allotransplantation of the Hand(s) and Face2641be91-6b2d-457f-9cb2-2fd6c8fd37045018Composite Tissue Allotransplantation of the Hand(s) and Face11.14.30
0614114f-9368-4ca8-bdcf-164d35718d22.aspx
  
05.00.37gCompressionGarments05.00.37gDME (05)Compression Garments0614114f-9368-4ca8-bdcf-164d35718d225172Compression Garments05.00.37
ddf4156a-01e2-4e9f-82fc-68aab25f027b.aspx
  
09.00.42cComputer-AidedDetection(CAD)SystemforUsewithChestRadiographs09.00.42cRadiology (09)Computer-Aided Detection (CAD) System for Use with Chest Radiographsddf4156a-01e2-4e9f-82fc-68aab25f027b5031Computer-Aided Detection (CAD) System for Use with Chest Radiographs09.00.42
92e3212a-d739-4d86-a4ac-39c40334f32d.aspx
  
11.14.17eComputer-assistedMusculoskeletalSurgicalNavigationalOrthopedicProcedure11.14.17eSurgery (11)Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure92e3212a-d739-4d86-a4ac-39c40334f32d5002Computer-assisted Musculoskeletal Surgical Navigational Orthopedic Procedure11.14.17
eb4b646a-6ce3-45f1-9096-23e49da996df.aspx
  
00.01.69bConsultationServices00.01.69bAdministrative (00)Consultation Serviceseb4b646a-6ce3-45f1-9096-23e49da996df5009Consultation Services00.01.69
96eca6bb-e268-40fb-89b6-dfeea7bb5fcc.aspx
  
07.13.11kContactLensesfortheTreatmentofPersistent(Corneal)EpithelialDefects07.13.11kMedicine (07)Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects96eca6bb-e268-40fb-89b6-dfeea7bb5fcc5065Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects07.13.11
{"5066": {"Id":5066,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":7217,"PolicyAttachmentPageName":"af801910-b372-4ab7-aa5f-2a44ef5a7a72"},}
7c8e4bb0-6f66-4f72-84b4-101428132497.aspx
  
09.00.11eContrastAgentsUsedinConjunctionwithEchocardiography09.00.11eRadiology (09)Contrast Agents Used in Conjunction with Echocardiography7c8e4bb0-6f66-4f72-84b4-1014281324975063Contrast Agents Used in Conjunction with Echocardiography09.00.11
fd6dafcb-2177-4721-b0e7-ea63c4a87e32.aspx
  
07.13.07lCornealPachymetryUsingUltrasound07.13.07lMedicine (07)Corneal Pachymetry Using Ultrasoundfd6dafcb-2177-4721-b0e7-ea63c4a87e325498Corneal Pachymetry Using Ultrasound07.13.07
{"5499": {"Id":5499,"MPAttachmentLetter":"A","Title":"ICD-10-CM codes","MPPolicyAttachmentInternalSourceId":7544,"PolicyAttachmentPageName":"5bd7c5ce-db96-4907-98e8-954ef96d6e7e"},}
5b51d048-2e6e-4a7e-9028-13d78b2d308e.aspx
  
09.00.58CoronaryArteryCalcium(CAC)TestingUsingComputedTomography(IndependenceAdministrators)09.00.58Radiology (09)Coronary Artery Calcium (CAC) Testing Using Computed Tomography (Independence Administrators)5b51d048-2e6e-4a7e-9028-13d78b2d308e5455Coronary Artery Calcium (CAC) Testing Using Computed Tomography (Independence Administrators)09.00.58
ab93aadf-f22e-4739-810d-e066c9b70846.aspx
  
12.01.03bCosmeticProcedures12.01.03bMiscellaneous (12)Cosmetic Proceduresab93aadf-f22e-4739-810d-e066c9b708465309Cosmetic Procedures12.01.03
6e97e871-9655-428c-b6b7-413c63b635b5.aspx
  
08.01.08nCoverageofAnticancerPrescriptionOralandInjectableDrugsandBiologicsandSupportiveAgents08.01.08nPharmacy (08)Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents6e97e871-9655-428c-b6b7-413c63b635b55650Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents08.01.08
{}
0e5a3246-799b-4df3-bc4a-9a5c0ec82166.aspx
  
05.00.04eCoverageofMedicalDevices05.00.04eDME (05)Coverage of Medical Devices0e5a3246-799b-4df3-bc4a-9a5c0ec821663665Coverage of Medical Devices05.00.04
58b083eb-8c60-4c11-8f00-e38c7be56b29.aspx
  
05.00.80cCranialElectrotherapyStimulation05.00.80cDME (05)Cranial Electrotherapy Stimulation58b083eb-8c60-4c11-8f00-e38c7be56b295518Cranial Electrotherapy Stimulation05.00.80
41b86d29-9dd9-419f-83a2-8f9b54f634da.aspx
  
05.00.25jCranialRemoldingOrthoses(Helmets)05.00.25jDME (05)Cranial Remolding Orthoses (Helmets)41b86d29-9dd9-419f-83a2-8f9b54f634da5594Cranial Remolding Orthoses (Helmets)05.00.25
1adfb9b5-6ec1-41a1-ab70-0ec7069d62d9.aspx
  
00.10.03kCriteriaforReimbursementofEmergencyRoomServices00.10.03kAdministrative (00)Criteria for Reimbursement of Emergency Room Services1adfb9b5-6ec1-41a1-ab70-0ec7069d62d94962Criteria for Reimbursement of Emergency Room Services00.10.03
ba1abd4b-b82f-4158-a09f-f27031b2634f.aspx
  
08.00.04acrizanlizumab-tmca(Adakveo®)08.00.04aPharmacy (08)crizanlizumab-tmca (Adakveo®)ba1abd4b-b82f-4158-a09f-f27031b2634f5640crizanlizumab-tmca (Adakveo®)08.00.04
5c410158-5c9f-4ee9-84e2-7e74e23e7cb1.aspx
  
11.11.03dCryosurgicalAblationoftheProstateGland11.11.03dSurgery (11)Cryosurgical Ablation of the Prostate Gland5c410158-5c9f-4ee9-84e2-7e74e23e7cb14309Cryosurgical Ablation of the Prostate Gland11.11.03
d5ec64eb-6e3a-4e18-ae7a-2e1f3d824f86.aspx
  
08.01.29jDaratumumab(Darzalex®),Daratumumab,andHyaluronidase-fihj(DarzalexFaspro®)08.01.29jPharmacy (08)Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®)d5ec64eb-6e3a-4e18-ae7a-2e1f3d824f864494Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®)08.01.29
1381b984-d385-4d3d-91a9-8daa23bf024f.aspx
  
10.00.02cDayRehabilitation10.00.02cRehabilitation Services (10)Day Rehabilitation1381b984-d385-4d3d-91a9-8daa23bf024f5297Day Rehabilitation10.00.02
9aaa0244-d519-4cc2-b31f-9604c858383c.aspx
  
11.08.17kDebridementofMycoticandSymptomaticNon-MycoticHypertrophicToeNails11.08.17kSurgery (11)Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails9aaa0244-d519-4cc2-b31f-9604c858383c5050Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails11.08.17
{"5051": {"Id":5051,"MPAttachmentLetter":"E","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (S86.892A - Z79.01), Continued","MPPolicyAttachmentInternalSourceId":7200,"PolicyAttachmentPageName":"6c8c7cfa-378c-406d-a02e-62621d3d9036"},"5052": {"Id":5052,"MPAttachmentLetter":"B","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E10.22 - E13.3512), Continued","MPPolicyAttachmentInternalSourceId":7201,"PolicyAttachmentPageName":"b8b7941f-bb7f-402f-8345-a5cfe9aa701e"},"5053": {"Id":5053,"MPAttachmentLetter":"D","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (I87.099 - S86.891S), Continued","MPPolicyAttachmentInternalSourceId":7202,"PolicyAttachmentPageName":"1b9df63e-76d7-492d-a66f-53868fc23379"},"5054": {"Id":5054,"MPAttachmentLetter":"A","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (A30.0 -E10.21)","MPPolicyAttachmentInternalSourceId":7203,"PolicyAttachmentPageName":"4a1f38b7-9d76-4aaa-920b-88cd4d7da417"},"5055": {"Id":5055,"MPAttachmentLetter":"C","Title":"ICD-10 CM Codes Eligible to be Reported for Debridement of mycotic hypertrophic toe nails (E13.3513 - I87.093), Continued","MPPolicyAttachmentInternalSourceId":7204,"PolicyAttachmentPageName":"ea01801d-1b6b-4cba-9abb-1723eb41d976"},}
04381ec2-e00a-43e6-8e98-f622150c3694.aspx
  
11.15.20sDeepBrainStimulation(DBS)11.15.20sSurgery (11)Deep Brain Stimulation (DBS)04381ec2-e00a-43e6-8e98-f622150c36945631Deep Brain Stimulation (DBS)11.15.20
a62acc79-9c13-49a6-a11c-c6ff9a940219.aspx
  
11.15.09pDenervationoftheSpinalNervesforChronicPain(IndependenceAdministrators)11.15.09pSurgery (11)Denervation of the Spinal Nerves for Chronic Pain (Independence Administrators)a62acc79-9c13-49a6-a11c-c6ff9a9402195163Denervation of the Spinal  Nerves for Chronic Pain (Independence Administrators)11.15.09
f7a4e448-7149-4f85-9802-fa101ddbe732.aspx
  
08.00.94qDenosumab(Prolia®,Xgeva®),Romosozumab-aqqg(Evenity®)08.00.94qPharmacy (08)Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)f7a4e448-7149-4f85-9802-fa101ddbe7325659Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®)08.00.94
{"5660": {"Id":5660,"MPAttachmentLetter":"A","Title":"ICD-10-CM Codes","MPPolicyAttachmentInternalSourceId":7711,"PolicyAttachmentPageName":"b43b6ce4-ade8-467e-9839-56e55a191eb6"},}
be28d21d-e730-431a-acf0-80cadcc53d6f.aspx
  
11.16.01kDermabrasionforRhinophyma,Septoplasty,Rhinoplasty,andSeptorhinoplasty11.16.01kSurgery (11)Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplastybe28d21d-e730-431a-acf0-80cadcc53d6f5559Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty11.16.01
e3772d4e-89a5-4eaf-b900-f06b47d8f372.aspx
  
00.03.02adDiagnosticRadiologyServicesIncludedinCapitation00.03.02adAdministrative (00)Diagnostic Radiology Services Included in Capitatione3772d4e-89a5-4eaf-b900-f06b47d8f3724935Diagnostic Radiology Services Included in Capitation00.03.02
{"4936": {"Id":4936,"MPAttachmentLetter":"A","Title":"Diagnostic Radiology Procedure Codes Included in Capitation for Pennsylvania (PA) Health Maintenance Organization (HMO) Members","MPPolicyAttachmentInternalSourceId":7126,"PolicyAttachmentPageName":"33d290db-40da-4a2b-b127-7b0176d5d6f8"},}
1 - 100Next